Patent ID: 8236764
Filing Date: 2012-08-07
Classification: A61K,A61P,C07K

Abstract:
1. A method for the treatment of a hemophilia A or hemophilia B in a patient in need thereof, comprising administering an effective amount of an activated form of factor V (FV), said activated form of FV selected from the group consisting of FV-810 (FV, SEQ ID NO: 1 lacking amino acid residues 811-1491); FV-859 (FV, SEQ ID NO: 1 lacking amino acid residues 860-1491; FV-866 (FV, SEQ ID NO: 1 lacking amino acid residues 867-1491); FV-902 (FV, SEQ ID NO: 1 lacking amino acid residues 903-1491); FV-924 (FV, SEQ ID NO: 1 lacking amino acid residues 923-1491); FV-937 (FV, SEQ ID NO: 1 lacking amino acid residues 938-1491); FV-956 (FV, SEQ ID NO: 1 lacking amino acid residues 957-1491); FV-1033-B58-s131 (FV, SEQ ID NO: 1 lacking amino acid residues 1034-1491 with amino acid residues 900-1030 exchanged with amino acid residues 907-1037 of factor VIII of SEQ ID NO: 2; FV-1033-B58-s104 (FV, SEQ ID NO: 1 lacking amino acid residues 1034-1491 with amino acid residues 904-1007 exchanged with amino acid residues 972-1075 of factor VIII of SEQ ID NO: 2); and FV-1033-B58-s46 (FV, SEQ ID NO: 1 lacking amino acid residues 1034-1491 with amino acid residues 963-1008 exchanged with amino acid residues 1032-1077 of factor VIII of SEQ ID NO: 2), thereby enhancing clot formation in said patient and ameliorating the symptoms of said hemophilia.